Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

by NASDAQ Market News November 6, 2019

NASDAQ Market News
Click here to email author

Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma

Trillium Therapeutics to Report Preclinical Data on Its STING Program at the SITC 34th Annual Meeting

Ads